Debie Y, Garcia-Fogeda I, Willem L, Roelant E, Verbruggen L, Vanhoutte G
Sci Rep. 2025; 15(1):7858.
PMID: 40050359
PMC: 11885447.
DOI: 10.1038/s41598-025-92254-8.
Oliveira K, Almeida A, Silva C, Brito M, Ribeiro E
Infect Dis Rep. 2024; 16(6):1084-1097.
PMID: 39728010
PMC: 11675320.
DOI: 10.3390/idr16060088.
Mink S, Saely C, Leiherer A, Reimann P, Frick M, Cadamuro J
JCI Insight. 2024; 9(20).
PMID: 39435658
PMC: 11529978.
DOI: 10.1172/jci.insight.183913.
Schoefbaenker M, Gunther T, Lorentzen E, Romberg M, Hennies M, Neddermeyer R
PLoS Pathog. 2024; 20(10):e1012624.
PMID: 39405332
PMC: 11508484.
DOI: 10.1371/journal.ppat.1012624.
Mink S, Drexel H, Leiherer A, Cadamuro J, Hitzl W, Frick M
Vaccines (Basel). 2024; 12(8).
PMID: 39203980
PMC: 11359237.
DOI: 10.3390/vaccines12080855.
Recent approaches in computational modelling for controlling pathogen threats.
Lees J, Russell T, Shaw L, Hellewell J
Life Sci Alliance. 2024; 7(9).
PMID: 38906676
PMC: 11192964.
DOI: 10.26508/lsa.202402666.
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review.
Sun Y, Huang W, Xiang H, Nie J
Vaccines (Basel). 2024; 12(5).
PMID: 38793805
PMC: 11125816.
DOI: 10.3390/vaccines12050554.
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Iwata S, Pollard A, Tada Y, Omoto S, Shibata R, Igarashi K
Sci Rep. 2024; 14(1):9830.
PMID: 38684712
PMC: 11059267.
DOI: 10.1038/s41598-024-57308-3.
Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2.
OMahoney C, Watt I, Fiedler S, Devenish S, Srikanth S, Justice E
Ann Biomed Eng. 2024; 52(6):1653-1664.
PMID: 38459195
PMC: 11082020.
DOI: 10.1007/s10439-024-03478-0.
Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials.
Goryaynov S, Gurova O
Vaccines (Basel). 2024; 12(2).
PMID: 38400114
PMC: 10892687.
DOI: 10.3390/vaccines12020130.
SARS-CoV-2 specific sIgA in saliva increases after disease-related video stimulation.
Keller J, Dulovic A, Gruber J, Griesbaum J, Schneiderhan-Marra N, Wulfing C
Sci Rep. 2023; 13(1):22631.
PMID: 38123577
PMC: 10733377.
DOI: 10.1038/s41598-023-47798-y.
Vaccine-induced SARS-CoV-2 antibody response: the comparability of S1-specific binding assays depends on epitope and isotype discrimination.
Schest S, Langer C, Stiegler Y, Karnuth B, Arends J, Stiegler H
Front Immunol. 2023; 14:1257265.
PMID: 37965324
PMC: 10641008.
DOI: 10.3389/fimmu.2023.1257265.
Association between sex hormones and anti-S/RBD antibody responses to COVID-19 vaccines in healthcare workers.
Anticoli S, Dorrucci M, Iessi E, Chiarotti F, Di Prinzio R, Vinci M
Hum Vaccin Immunother. 2023; 19(3):2273697.
PMID: 37961893
PMC: 10760357.
DOI: 10.1080/21645515.2023.2273697.
Monoclonal Antibodies as SARS-CoV-2 Serology Standards: Experimental Validation and Broader Implications for Correlates of Protection.
Wang L, Patrone P, Kearsley A, Izac J, Gaigalas A, Prostko J
Int J Mol Sci. 2023; 24(21).
PMID: 37958688
PMC: 10650176.
DOI: 10.3390/ijms242115705.
Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective cohort study.
Mink S, Saely C, Leiherer A, Frick M, Plattner T, Drexel H
Sci Rep. 2023; 13(1):18326.
PMID: 37884649
PMC: 10603091.
DOI: 10.1038/s41598-023-45700-4.
Dynamics of immunity over time: decline of anti-SARS-CoV-2 IgG antibodies and T-cell responses after mRNA vaccination in residents and health care workers in nursing homes and homes with assisted living support.
Schiffner J, Eisemann N, Baltus H, Jensen S, Wunderlich K, Schuesseler S
GMS Infect Dis. 2023; 11:Doc02.
PMID: 37830111
PMC: 10565841.
DOI: 10.3205/id000082.
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Leal L, Pich J, Ferrer L, Nava J, Marti-Lluch R, Esteban I
NPJ Vaccines. 2023; 8(1):147.
PMID: 37775521
PMC: 10541407.
DOI: 10.1038/s41541-023-00736-5.
Effectiveness of Mix-and-Match Vaccination in Preventing SARS-CoV-2 Omicron Variant Infection in Taiwan: A Test-Negative Control Study.
Huang Y, Chen Y, Chuang C, Chang S, Chiu C
Vaccines (Basel). 2023; 11(9).
PMID: 37766119
PMC: 10535833.
DOI: 10.3390/vaccines11091441.
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.
Kroidl I, Winter S, Rubio-Acero R, Bakuli A, Geldmacher C, Eser T
Virol J. 2023; 20(1):200.
PMID: 37658454
PMC: 10474769.
DOI: 10.1186/s12985-023-02167-z.
Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2.
Muller S, Paltra S, Rehmann J, Nagel K, Conrad T
iScience. 2023; 26(9):107554.
PMID: 37654471
PMC: 10466916.
DOI: 10.1016/j.isci.2023.107554.
